TVARDI THERAPEUTICS ADVANCES NEXT-GENERATION ORAL STAT3 INHIBITOR TTI-109 TOWARD IND IN INFLAMMATORY BOWEL DISEASE FOLLOWING FDA PRE-IND FEEDBACK

Reuters · 2d ago

Please log in to view news